×

Stocks Arena Pharmaceuticals Inc

  • obesity_woman_200.jpg

    There are a growing number of investing opportunities in  companies aiming to stem the tide of obesity—whether upstart biotechs, organic grocers, fitness chains, or weight-loss specialists.

  • In the quest to help Americans fight the battle of the bulge 3 new pills may be coming to market by the end of the year. What must you know?

  • fda_medicine_200.jpg

    FDA advisory committee votes sometimes end in confusion. First, because the actual vote often gets all convoluted and recounted as some panelists hem and haw about voting thumbs up or thumbs down and try to equivocate their decision. And second, because no matter how many times I've explained it to people here, the votes get misread and miscommunicated as actual approval or rejection of a drug versus a recommendation that the FDA clear or spike a drug.

  • Vivus announced this morning that an FDA advisory committee is tentatively scheduled to take a look at its diet drug Qnexa on Thursday, July 15th.

  • Stocks rallied Wednesday as the dollar pulled back and Fed Chairman Ben Bernanke pledged to keep rates low for a long time. Financials were among the top gainers.

  • Stocks rallied Wednesday as the dollar pulled back and Fed Chairman Ben Bernanke pledged to keep rates low for a long time. Financials were among the top gainers.

  • Stocks opened slightly higher Wednesday as the market looked for direction ahead of Fed Chairman Ben Bernanke's semi-annual report on monetary policy and the economy.

  • vivus_200.jpg

    The Financial Industry Regulatory Authority, the stock markets' self-policing arm, is looking into trading in Vivus shares around the time it announced its positive late-stage test results on its diet drug, Qnexa.

  • Vivus is getting the JPMorgan Healthcare Conference off to a sexy start. The company announced this morning that its late-stage experimental erectile dysfunction drug apparently gets the job done in 15 minutes.

  • pills_prescription_200.jpg

    I can’t wait until this drug rises to the level where it gets on Joe Kernen’s radar screen because, boy, is he gonna have a good time (not just with the drug perhaps, but mostly with talking on TV about it.) A little TMI, I know, but that’s Joe.

  • obesity_man_200.jpg

    I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill.

  • Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months.

  • Stocks resumed their ascent Friday, after snapping the week's winning streak on Thursday, as investors braced for a volatile day due to quadruple witching.

  • Stocks resumed their ascent Friday, after snapping the week's winning streak on Thursday, as investors braced for a volatile day due to quadruple witching.

  • There! I resisted writing a blog headline that attempts some tired play on words with the Arena Pharmaceuticals' clinical trial acronyms BLOSSOM and BLOOM.

  • Stocks resumed their ascent Friday, after snapping the week's winning streak on Thursday, as investors braced for a volatile day due to quadruple witching.

  • Stock index futures pointed to a slightly higher open for Wall Street, with no significant economic news but quadruple-witching on the table.

  • cadeuses2.jpg

    Today is the 16th annual "Newsmakers in Biotech" event put on by Thomson Reuters and BioCentury.

  • Qnexa

    Some analysts had been telling clients recently that they thought Vivus' diet drug Qnexa could take the lead in the three-contestant race to get the next prescription diet pill on the market. But they didn't think it would take such a commanding lead.

  • This company’s diabetes and obesity drug could generate huge returns for investors.